• Scientific
• Dublin, Ireland
• October 11 - 12, 2007
• Symphogen participants: Klaus Koefoed, Senior Scientist

Trevor Wattam, GlaxoSmithKline, UK
"High Throughput Monoclonal Antibody Screening using the Biacore A100"

Kenneth Miller, MedImmune, USA
"Use of SPR Biosensors in the Characterization of Therapeutic mAbs" 

Tony Newcombe, Protherics, UK
"Evaluation of Biacore Technology for Biopharmaceutical Development" 

Mathilde Cabrit, Serono, France
"Biacore C versus other methods for Ab and fusion protein quantification in cell culture and purification processes" 

Daniel Mytych, Amgen, USA
"Immunogenicity of Therapeutic Proteins" 

Annette Zaar, Novartis, Switzerland
"Detection of Anti-Drug Antibodies (ADA) in the presence of excess Therapeutic Antibody" 

Thomas Urbig, Micromet, Germany
"The Use of Surface Plasmon Resonance Spectroscopy from Development into Early Biomanufacturing" 

Cornelius Fritsch, Novartis, Switzerland
"Effector Functions of Therapeutic Monoclonal Antibodies: Analysis Using Biacore Technology" 

Fredrik Sundberg, GE Healthcare, Sweden
"From a Global Industry Perspective: SPR Biosensor Strategies to
Improve Bio-therapeutic Discovery and Development" 

Gregory de Crescenzo , École Polytechnique de Montréal, Canada
"On-line Monitoring of Bioreactor Protein Production by Surface Plasmon Resonance" 

Bruce Carrington , UCB Celltech, Slough, UK
"Antibody screening prior to cloning" 

Alistair Henry , UCB Celltech, Slough, UK
"Antibodies, epitopes and mechanism of action'" 

Danièle Altschuh , Centre National de Recherche Scientifique, France
"SPR characterization of gastrin binders, for the development of anti-gastrin therapies in pancreatic cancer" 

David Thakor , GSK, Beckenham, UK
"Delivering next generation Biacore assays into the QC environment" 

Martin Hülsmeyer, Pieris AG, Freising, Germany
"The role of SPR based assays in the discovery and lead optimization of Anticalins®, a novel class of therapeutic binding proteins"